BioCentury
ARTICLE | Company News

Argos, Chongqing Lummy Pharmaceutical deal

April 20, 2015 7:00 AM UTC

Argos granted Chongquing Lummy’s Lummy Co. Ltd. subsidiary exclusive rights in China, including Hong Kong and Macau, and Taiwan to develop and commercialize AGS-003 for oncology indications. Argos is conducting the Phase III ADAPT study of the second-generation RNA-loaded autologous dendritic cell immunotherapy to treat metastatic renal cell carcinoma (RCC). Lummy said it may develop AGS-003 to treat pancreatic, lung, liver, stomach, rectal, gastric and/or esophageal cancers. Lummy will be responsible for development costs required for approval.

Lummy also gained an option to develop and commercialize Argos’ AGS-004, an autologous dendritic cell immunotherapy transfected with the patient’s viral RNA antigens. It is in Phase II testing to treat chronic HIV-1 infection. ...